



Nephrotic Syndrome: Pathomechanism, Diagnostics and Novel Treatment Options

Guest Editor:

Dr. Kan Katayama

Department of Cardiology and
Nephrology, Mie University
Graduate School of Medicine, 2-
174 Edobashi, Tsu 514-8507, Mie,
Japan

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Nephrotic syndrome (NS) is characterized by massive proteinuria, hypoproteinemia, and edema, and it is divided into steroid-sensitive NS (SSNS) and steroid-resistant NS (SRNS). While SSNS typically presents with minimal change NS, SRNS typically presents with focal segmental glomerulosclerosis (FSGS), which often leads to end-stage kidney failure. About 30% of cases of childhood-onset FSGS have been found to be hereditary FSGS caused by dozens of podocyte-related genes, and about 5-10% of cases of adult-onset FSGS have also been found to be hereditary FSGS.

The aim of this Special Issue is to gather original research articles and review articles that focus on NS. Articles focused on genetic forms of kidney disease are especially encouraged.

Dr. Kan Katayama

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)